Orchard Venture Partners

Verlume specializes in subsea power hub technology that focuses on generating, storing, and supplying electrical power from ocean currents and tides. The company's innovative solutions are designed to help clients in underwater, offshore, and onshore sectors reduce their carbon footprint and decarbonize their operations. By converting renewable energy from marine environments into usable electrical power, Verlume enables its clients to harness clean energy while minimizing environmental impact.

GuideCX, Inc. is a company that specializes in client onboarding and project implementation software, designed to facilitate a smooth transition between sales and implementation processes. Founded in 2017 and based in Draper, Utah, GuideCX serves a variety of industries, including software as a service (SaaS), automotive, education, finance, and health. The platform enables users to automate tasks, view project statuses, and communicate updates effectively, providing a transparent experience for clients. With over 300,000 successful onboarding projects completed, GuideCX emphasizes engagement and efficiency, offering customizable templates and purpose-built integrations that enhance user experience. The platform is designed for easy integration with existing customer relationship management systems and includes robust reporting features to help manage customer expectations and improve overall project outcomes.

Verlume specializes in subsea power hub technology that focuses on generating, storing, and supplying electrical power from ocean currents and tides. The company's innovative solutions are designed to help clients in underwater, offshore, and onshore sectors reduce their carbon footprint and decarbonize their operations. By converting renewable energy from marine environments into usable electrical power, Verlume enables its clients to harness clean energy while minimizing environmental impact.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for kidney diseases. Its primary product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD), including those on dialysis. The company is also advancing vadadustat, an oral treatment for anemia associated with CKD, which is currently in Phase III trials. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, including the United States and Japan. Additionally, Akebia has a research and license agreement with Janssen Pharmaceutica NV to develop compounds targeting hypoxia-inducible factor prolyl hydroxylases. Founded in 2007, Akebia is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for kidney diseases. Its primary product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD), including those on dialysis. The company is also advancing vadadustat, an oral treatment for anemia associated with CKD, which is currently in Phase III trials. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, including the United States and Japan. Additionally, Akebia has a research and license agreement with Janssen Pharmaceutica NV to develop compounds targeting hypoxia-inducible factor prolyl hydroxylases. Founded in 2007, Akebia is headquartered in Cambridge, Massachusetts.

Base4 Biotechnology is focused on advancing RNA-targeted therapeutics through innovative small molecule modulation aimed at addressing previously untreatable diseases. Utilizing a proprietary structure-based discovery platform, the company integrates advanced computational technologies with experimental validation to explore and unlock the potential of RNA targets. This approach allows Base4 to tackle complex diseases across various therapeutic areas, including neurology, oncology, and rare diseases. By bridging the gap between computational discovery and practical application, Base4 aims to contribute significantly to the development of transformative medicines in the healthcare industry.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for kidney diseases. Its primary product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD), including those on dialysis. The company is also advancing vadadustat, an oral treatment for anemia associated with CKD, which is currently in Phase III trials. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, including the United States and Japan. Additionally, Akebia has a research and license agreement with Janssen Pharmaceutica NV to develop compounds targeting hypoxia-inducible factor prolyl hydroxylases. Founded in 2007, Akebia is headquartered in Cambridge, Massachusetts.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for patients with hematology and oncology needs. The company's lead drug candidate, momelotinib, is an orally bioavailable inhibitor targeting JAK1, JAK2, and ACVR1, which has undergone two completed Phase 3 trials for myelofibrosis treatment. Additionally, Sierra Oncology is advancing SRA737, a small molecule inhibitor of Checkpoint kinase 1 currently in Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase, which is in preclinical development. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology aims to provide targeted therapies for rare forms of cancer, leveraging scientific expertise to address limitations in existing treatments and improve patient outcomes. The company was previously known as ProNAi Therapeutics, Inc. before its name change in January 2017.